AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML

PRESS RELEASEAB SCIENCE REPORTS COMPLETION OF THE STEP 3 OF PHASE 1, EVALUATING THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ...
Yahoo Finance

AB Science provides an update on its clinical development program.

AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd's Syndicate 1902, for its Phase III clinical trial ...
Yahoo Finance

AB Science will publish its 2024 annual financial report on May 9, 2025

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...
Morningstar

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

AB Science SA (Euronext - FR0010557264 - AB) today announced that the Chinese Patent Office has issued a patent relating to methods of treating severe acute respiratory syndrome coronavirus 2 ...
Hosted on MSN

Ab Science’s Phase 3 ALS Trial: A Key Development for Investors

Ab Science ((ABSCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Hosted on MSN

FDA and EMA authorise AB Science’s Phase III trial of prostate cancer treatment

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib in treating metastatic ...
manilatimes

AB Science reports its revenues for the year 2025 and provides an update on its activities

i) Approval by several European countries to initiate the confirmatory Phase 3 trial AB Science announced in July 2025 that the confirmatory Phase 3 trial with masitinib in amyotrophic lateral ...
Finanznachrichten

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease (i.e ...
Finanznachrichten

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

AB Science SA (Euronext - FR0010557264 - AB) today announces that The Life Sciences Magazine, a leading publication in the fields of healthcare and medical advancements, has featured an exclusive ...